Deal Tracker · Regions

MENA pharma joint ventures

3 joint venture deals in MENA tracked by EPT (2020–2026). Most active: Dawah Pharma, G42, HoldiPharma & SaudiVax. Latest: Dawah Pharma → HoldiPharma (Joint venture, 5 Nov 2026).

3
deals tracked
1
announced in 2026
—
values undisclosed
100%
joint ventures, the top deal type
  • EPT has tracked 3 MENA pharma joint ventures (2020–2026), 1 of them announced in 2026.
  • The countries that appear most often are China (2), Egypt (1), Saudi Arabia (1) & Türkiye (1).
  • None of these deals disclosed a value, which is common for licensing and distribution agreements in these markets.

Countries involved

China (2) · Egypt (1) · Saudi Arabia (1) · Türkiye (1) · UAE (1) · United States (1)

Questions

How many MENA pharma joint ventures has EPT tracked?
3 as of 5 Nov 2026, covering 2020–2026; 1 were announced in 2026. The most recent is Dawah Pharma → HoldiPharma (Joint venture, 5 Nov 2026).
Which countries appear most in MENA pharma joint ventures?
China (2), Egypt (1), Saudi Arabia (1), Türkiye (1), UAE (1), United States (1) — counting where the parties are based and the markets the deals cover.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)